Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group
Antiviral Res. 2021 Aug 4:105158. doi: 10.1016/j.antiviral.2021.105158. Online ahead of print.ABSTRACTIt is more than 20 years since the neuraminidase inhibitors, oseltamivir and zanamivir were approved for the treatment and prevention of influenza. Guidelines for global surveillance and methods for evaluating resistance were established initially by the Neuraminidase Inhibitor Susceptibility Network (NISN), which merged 10 years ago with the International Society for influenza and other Respiratory Virus Diseases (isirv) to become the isirv-Antiviral Group (isirv-AVG). With the ongoing development of new influenza polymer...
Source: Antiviral Research - August 7, 2021 Category: Virology Authors: Michael G Ison Frederick G Hayden Alan J Hay Larisa V Gubareva Elena A Govorkova Emi Takashita Jennifer L McKimm-Breschkin Source Type: research
Association between anaphylaxis and anti-influenza drug use: An analysis of the Japanese Adverse Drug Event Report database
Drug Discov Ther. 2021;15(3):150-155. doi: 10.5582/ddt.2021.01053.ABSTRACTWe aimed to investigate the association between anaphylaxis and anti-influenza drug use using the Japanese Adverse Drug Event Report (JADER) database, a national spontaneous reporting database in Japan. We surveyed registered cases from the JADER database between April 2004 and November 2019. The target drugs were five anti-influenza drugs, namely oseltamivir, zanamivir, peramivir, laninamivir, and baloxavir. Adverse events associated with anaphylaxis, "anaphylactic reaction," "anaphylactic shock," "anaphylactoid reaction," and "anaphylactoid shock,"...
Source: Drug Discoveries and Therapeutics - July 8, 2021 Category: Drugs & Pharmacology Authors: Hiroyuki Tanaka Katsuhiro Ohyama Yui Horikomi Toshihiro Ishii Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
Computational screening of dual inhibitors from FDA approved antiviral drugs on SARS-CoV-2 spike protein and the main protease using molecular docking approach
Acta Virol. 2021;65(2):160-172. doi: 10.4149/av_2021_208.ABSTRACTThe deadly disease-causing novel coronavirus has recently swept across the world and endangered many human lives. Although, various research on therapeutic measures to solve this pandemic crisis has been published; no favourable results have been achieved. We propose the use of potential FDA-approved dual inhibitors which can inhibit two targets (either on entry-level or the main protease) for the effective treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We screened 12 FDA-approved antiviral inhibitors listed in Drug bank and analys...
Source: Acta Virologica - June 16, 2021 Category: Infectious Diseases Authors: Shanthi Sabarimurugan Indu Purushothaman Rajarajan Swaminathan Arun Dharmarajan Sudha Warrier Sangeetha Kothandan Source Type: research
